Home » Stocks » MNK

Mallinckrodt PLC (MNK)

Oct 13, 2020 - MNK was delisted due to bankruptcy and now trades as MNKKQ
Stock Price: $0.750 USD 0.000 (0.00%)
Updated Oct 12, 2020 4:00 PM EDT

Stock Price Chart

Key Info

Market Cap 63.44M
Revenue (ttm) 2.38B
Net Income (ttm) -2.14B
Shares Out 84.59M
EPS (ttm) -25.44
PE Ratio n/a
Forward PE 0.45
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 12, 2020
Last Price $0.750
Previous Close $0.750
Change ($) 0.000
Change (%) 0.00%
Day's Open -
Day's Range 0.750 - 1.000
Day's Volume 0
52-Week Range 0.750 - 6.420

More Stats

Market Cap 63.44M
Enterprise Value 4.49B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 84.59M
Float 83.49M
EPS (basic) -25.45
EPS (diluted) -25.44
FCF / Share 4.89
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 651.62%
Payout Ratio n/a
Shares Short 41.72M
Short Ratio 10.58
Short % of Float 49.98%
Beta 3.06
PE Ratio n/a
Forward PE 0.45
P/FCF Ratio 0.15
PS Ratio 0.03
PB Ratio 0.01
Revenue 2.38B
Operating Income -2.54B
Net Income -2.14B
Free Cash Flow 413.40M
Net Cash -4.42B
Net Cash / Share -52.31
Gross Margin 60.12%
Operating Margin -106.66%
Profit Margin -89.90%
FCF Margin 17.36%
ROA -2.36%
ROE -107.26%
ROIC -31.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (5)

Buy 0
Overweight 0
Hold 3
Underweight 0
Sell 2

Analyst Consensus: Hold

Price Target

$1.50*
(100.00% upside)
Low
1.00
Current: $0.750
High
2.00
Target: 1.50
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue3,1633,2163,2223,3812,9231,6501,7122,0562,0222,048
Revenue Growth-1.65%-0.19%-4.71%15.66%77.13%-3.62%-16.73%1.7%-1.26%-
Gross Profit1,4211,4711,6581,8581,623885822965915932
Operating Income-1,822-3,72149363335443.4073.50235241237
Net Income-997-3,6072,134644325-31958.80135151201
Shares Outstanding83.9084.0097.7011111664.9057.7057.7057.70-
Earnings Per Share-11.88-42.9421.805.772.75-4.921.022.332.61-
EPS Growth--277.82%109.82%---56.22%-10.73%--
Operating Cash Flow7436667271,185931373136256370402
Capital Expenditures-133-127-186-183-148-128-148-144-120-104
Free Cash Flow6105395411,002783246-12.00112250299
Cash & Equivalents7913491,415281366708276---
Total Debt5,3756,0926,7356,0456,4963,89592010.2011.70-
Net Cash / Debt-4,584-5,743-5,320-5,765-6,130-3,187-644-10.20-11.70-
Assets10,33910,87715,28115,49916,40412,7873,5572,8992,823-
Liabilities8,3987,9908,75910,22811,0937,8292,3011,0071,035-
Book Value1,9412,8876,5225,2715,3114,9581,2561,8921,789-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Mallinckrodt PLC
Country Ireland
Employees 3,400
CEO Mark C. Trudeau

Stock Information

Ticker Symbol MNK
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NYSE: MNK

Description

Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers Acthar Gel, an injectable drug for rheumatoid arthritis, multiple sclerosis, infantile spasms, systemic lupus erythematosus, polymyositis, and others; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; and Therakos photopheresis, an immunotherapy treatment platform, as well as Amitiza, a product for constipation. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; StrataGraft, which is in Phase III and II clinical development for the treatment of burns; MNK-6105 and MNK-6106, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; and SLN500, a ribonucleic acid technology therapy. It markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc. The company was founded in 1867 and is based in Dublin, Ireland. On October 12, 2020, Mallinckrodt plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.